You Position: Home > Paper
Reversing effects of cyclooxygenase-2 inhibitor celecoxib on multi-drug resistance of SGC7901/VCR gastric carcinoma line
( views:250, downloads:4 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1006-9801.2007.01.004
- Key Word:
- 胃肿瘤;环氧合酶;抗药性,多药;塞莱昔布
Abstract： 目的 观测环氧合酶-2(COX-2)抑制剂塞莱昔布(Celecoxib)对多药耐药细胞株SGC7901/VCR多药耐药(MDR)的逆转及P-糖蛋白(P-gp)的调变作用,探讨COX-2对胃癌细胞MDR调节作用.方法 以长春新碱(VCR)诱导的人胃癌多药耐药细胞SGC7901/VCR为研究对象,应用流式细胞术、MTT法及免疫细胞化学方法研究COX-2抑制剂塞莱昔布对耐药性的逆转作用及对P-gp的调变作用.结果 MTT显示塞莱昔布明显抑制SGC7901、SGC7901/VCR细胞的生长,并呈时间、剂量依赖性.经非细胞毒剂量(2.5 μmol/L)的塞莱昔布作用后,SGC7901/VCR细胞的多药耐药性得到部分逆转,表现为靶细胞对多种化疗药物的敏感性显著增加,逆转倍数为1.09～6.28;流式细胞仪分析发现,塞莱昔布介导的SGC7901/VCR细胞耐药性的逆转伴有胞内多柔比星浓度的升高;免疫细胞化学研究显示,经塞莱昔布作用后耐药株SGC7901/VCR表达P-gp强度下降.结论 塞莱昔布能有效地抑制肿瘤细胞的生长,且部分逆转SGC7901/VCR细胞的多药耐药性,其可能主要通过影响P-gp的药物泵功能实现.
- [1]刘军,朱海杭,卜平,等.环氧合酶-2、P-gp在胃癌组织中的表达及其意义[J].2004,(2).
- [2]Taylor PR,Tangrea JA,Daschner PJ,etc.Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?[J].2001,21(3C).
- [3]Toyoaki, Hida,Ken-Ichi, Kozaki,Hidemi, Ito,etc.Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.[J].2002,8(7).
- [4]Gordon GB,Hawk E,Wallace MH,etc.The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.[J].2000,342(26).
- [5]Sorokin A,Patel VA,Dunn MJ.Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2.[J].2002,277(41).
- [6]T O, Daniel,H, Liu,J D, Morrow,etc.Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.[J].1999,59(18).
- [7]Jaspers I,Kwon P,Rotem R,etc.Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells.[J].2000,20(6B).
- [8]O'Mahony CA,Berger DH,Dubois RN,etc.Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis.[J].1999,126(2).
- [9]J L, Masferrer,K M, Leahy,A T, Koki,etc.Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.[J].2000,60(5).